Pfizer’s Lyrica (pregabalin) is the first drug approved by the FDA in the treatment of fibromyalgia. Lyrica reduces pain for fibromyalgia patients. Exactly how it does this is still unknown, but data suggest that it effects neurotransmitters in the brain—the chemical that influences which signals are transmitted successfully from one neuron to another.

The effectiveness was studied in two double-blind studies of about 1,800 fibromyalgia sufferers. Those receiving Lyrica were given doses ranging from 300-450 mg daily were found to have less pain. The higher pain level returned when the subjects were no longer being given the drug.

Most common side effects include dizziness and sleepiness, blurry vision, weight gain, trouble concentrating, swelling of the hands and feet, and dry mouth. Allergic reactions have also occurred. The potentially serious side-effects are considered rare.